Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production

Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo's site in Monksland, Athlone, is one of 16 facilities the company has across the world. The expansion of the 45-acre tabletting facility is expected to be completed by 2028, though construction has already begun. The site's existing 260 employees will focus on delivering oral glucagon-like peptide-1 receptor agonists (GLP- 1RAs). The Danish ...